| Rheumatoid Arthritis
Rayos vs Xeljanz
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Rayos vs Xeljanz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXeljanz has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xeljanz but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Xeljanz
At A Glance
Oral
Daily
Corticosteroid
Oral
Twice daily
JAK inhibitor
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
- Juvenile polyarthritis
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).
Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.
Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.
Contraindications
- Known hypersensitivity to prednisone or any excipient
—
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.
Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.
Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Xeljanz
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xeljanz
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Xeljanz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
No savings programs available for Xeljanz.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XeljanzView full Xeljanz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.